The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10
| Autor: | Fadi Bou-Abdallah, Vivian Yaci Yu, Robert P. Doyle, Brian P. Huta, Allison M. Roberts, E. S. Waters, M. R. Mehlenbacher |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Pharmacology
Coenzyme Q10 Drug media_common.quotation_subject Organic Chemistry Pharmaceutical Science Transporter Biology Human serum albumin Biochemistry Bioavailability chemistry.chemical_compound chemistry In vivo Coenzyme Q – cytochrome c reductase Drug Discovery medicine Molecular Medicine Atovaquone medicine.drug media_common |
| Zdroj: | Med. Chem. Commun.. 5:787-791 |
| ISSN: | 2040-2511 2040-2503 |
| DOI: | 10.1039/c3md00373f |
| Popis: | Atovaquone is a front-line antimalarial drug that functions by competitively inhibiting binding of coenzyme Q10 to the cytochrome bc1 complex. Atovaquone is administered orally, but has low solubility and is poorly absorbed with high variability in bioavailability. In vivo binding of human serum albumin has been cited as the major transporter of atovaquone in plasma. The research presented herein demonstrates that saposin B, a known binder/transporter of coenzyme Q10, also binds to atovaquone in a 1 : 1 ratio and with comparably high affinity at pH 5.5. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|